SCHEMBL8298564

SCHEMBL8298564

Cc1ccc(OC(=O)N2CCN(C(=O)C(F)(F)F)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CHRNA7 P36544 1/20 0.46
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.43
TRPV1 Q8NER1 2/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13004298 0.84 ALOX15 (0.58) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL15134826 0.81 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL8235480 0.80 ALDH1A1 (0.79) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL13043643 0.80 CYP2C19 (0.63) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL10246301 0.80 CYP1A2 (0.63) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL12994617 0.79 ALDH1A1 (0.82) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL8747161 0.78 ALDH1A1 (0.79) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL8247308 0.76 CYP1A2 (1.00) CYP1A2CYP2C9CYP2C19POLBRAB9A
SCHEMBL653157 0.76 CYP1A2 (0.67) CYP1A2CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL5426988 0.76 CYP1A2 (0.67) CYP1A2CYP2C9CYP2C19ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258399-A2 Multivalent VLA-4 antagonists comprising polymer moieties Elan Pharmaceuticals Inc. (US) 2010-12-08 EP disclosed
WO-2005000244-A2 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS ELAN PHARMACEUTICALS, INC. (US) 2005-01-06 WO disclosed